Responsible and closely supervised pharmaceutical branch
The pharmaceutical branch shoulders a huge responsibility for people's health and wellbeing.
Our experts work incessantly for the health and wellbeing of people. PIF’s member companies allocated as much as 20% of the result to the development of novel therapies – to improve people’s quality of life, to cure and even prevent more diseases. The branch also brings hope of getting better to those who do not yet have it.
We also carry our societal responsibility. Novel therapies can generate significant cost savings for the social welfare and healthcare system, thereby also bridging the sustainability gap worrying the ageing country.
Since we work with people’s health, it is very important that this branch is also tightly regulated and supervised. Working under the Ministry of Social Affairs and Health, the Finnish Medicines Agency Fimea is the supervisory authority for medicine safety, manufacturing, use, sale and marketing. We collaborate seamlessly and openly with the our regulatory authorities, and we value such cooperation highly
Click here to read more about the cooperation with the authorities.